Btg Share Discussion Threads

[cockneytrader] 11/7/2018 15:04

Fhmktg - Are you going to the agm?

[cockneytrader] 11/7/2018 14:58

This pseudo capitalism makes me very cross. Rewards for failure. U.K. Pharma, U.K. House builders, the list goes on. The directors need to start buying these shares pronto, they need supporting!

[a1ord53] 11/7/2018 14:54

Rise and Fall of Maikin fraudulent and incompetent managing, woodford‘s creation.
After she wasted shareholders funds and let US court penalise shareholders by judgement , she took bonuses in millions - she should prosecuted imo.

[fhmktg] 11/7/2018 14:51

Unless I've missed something, no major holder has jumped ship since the start of 2018?It seems that short trading on a steady basis has been responsible for the drop after the PneumRx 'news'Apart from the expected agm matter around the previousFDs bonuses, nothing has materially changed since the new year and that has cost me dear!Am I missing something.If not then the statements at the agm are critical to stopping the rot.Questions will no doubt come from analysts as to the prospects for Varithena and Crofab and the clarity or lack of it in the answers will define the outcome.If negative, then my faith over 15years in British healthcare ventures will have been an abject failure!

[cockneytrader] 11/7/2018 14:46

It's as bad as England taking penalties - I just can't watch!

[spyder] 11/7/2018 14:40

Profit warning in the pipeline? New FD wanting to clear the decks?
CEO's position looking fragile.
Where is Jan du Plessis when you need him!!

[cockneytrader] 11/7/2018 14:36

I was expecting some stabilisation at around £5 in the aftermath of Pneumerx news, however there seems to be no share price floor!

[cockneytrader] 11/7/2018 14:27

Does somebody know something we don't? The rate of this fall is unprecedented considering no recent RNS.

[steeplejack] 11/7/2018 10:47

The Trump administration will actively encourage generics.Saves money.

[cockneytrader] 11/7/2018 09:03

The inherent risk of generic competition is clear to see with Indivior, down over 30% this morning. This is one of my concerns with reference to CroFab, a true star with revenue in the region of £80m per annum and a hefty profit margin.

[spyder] 11/7/2018 08:55

The clever analysts have targets of £4-£5.
Or perhaps it is not so much a case of being clever, but more due to the fact that they have chosen to make their own judgement about BTG's prospects rather than listen to the fantasy spouted by company.
I'm still looking forward to the $1bn turnover target that we have been lead to believe is around the corner.

[cockneytrader] 11/7/2018 08:40

Sad really. And who are these analysts with target prices in the region of £8-9?

[semper vigilans] 11/7/2018 08:39

Their own pockets rather than those of others.

[cockneytrader] 11/7/2018 08:31

Directors need to put their hands in their pockets.

[spyder] 11/7/2018 08:30

In my view, there is no prospect now for the company to takeover any further companies or buy in any further products with the current management in place as the share price has been trashed, the reputation of the company is in tatters, and who would trust the executives to deliver what they promise with any new products given their appalling approach to Vistogard, and hopeless approach to other products.
Time for change ...

[spyder] 11/7/2018 08:25

You also wonder how on earth anyone could think tha it was a good idea for the departed FD to be allow to keep his FUTURE bonuses in light of the Vistogard judgement, and the shambolic approach to cost cuts in Specialty Pharma that surrounds the case and will have ended up costing the Co the best part of $100m!!!
Why should the shareholders bear all the pain and the executives all the gain?
Come on Garry, it is time for you to do YOUR job.

[fhmktg] 11/7/2018 08:20

Like trying to catch a falling knife!

[spyder] 11/7/2018 08:17

The last time we closed at these levels was 2013!

[spyder] 11/7/2018 08:15

And the shares keep falling ...

[semper vigilans] 11/7/2018 07:46

Well put Bob.
Clawback of bonuses? I doubt it.

[bargainbob] 11/7/2018 07:42

The best shareholders could hope for is a takeover. Glassdoor reviews do not paint management in a better light than the above unfortunately. As a long term BTG holder , so sad to see good windfalls wasted and diverted to mangers via bonus payments . I do not know how Louise can survive this , though I fear if she went it would be another blow to the share price. I also believe any takeover would be at around the current price.

[spyder] 10/7/2018 18:39

The Judgement from the Vistoguard case makes very interesting reading if you have the time.

There is a lot of information in there suggesting serious questionable management practices, NONE of which reflect well on BTG.

I hope someone is able to ask the Board to comment about this at the AGM. It surprises me that the Chairman hasn't taken action yet.

hxxps://courts.delaware.gov/Opinions/Download.aspx?id=262000

Here are just a few direct quotes from the Judge's verdict:

Moody also understood that the oncology sales force was too small, and he continued to advocate for more support for Vistogard. In January 2016, BTG fired him. When he ran into some Wellstat executives, Moody confided that he had been fired for “pushing too hard for Vistogard internally.”

I find that BTG falsified its model to conceal that its sixteen-person sales force could not provide adequate support for Vistogard.

On March 2, 2016, BTG sent Wellstat a seven-year sales forecast. To hide its manipulation of the data, BTG did not send the underlying spreadsheets. BTG only disclosed the annual revenue numbers. BTG claimed that its model forecasted $39.8 million in revenue in the third year and $56 million in revenue in the seventh year. These statements were knowingly and intentionally false.

On July 5, 2016, a BTG employee reported that “the existing reps are already very frustrated at their lack of training on Vistogard, and the new ones never had any formal training on Voraxaze. I don’t understand why [BTG management is] unwilling to train the new reps appropriately.”; The answer is that BTG had not supported Vistogard adequately and was trying to cover up its failure to meet its obligations.

Wellstat correctly points out that BTG acted aggressively and took disingenuous positions during the litigation. In discovery, BTG refused to produce documents relating to BTG’s strategic shift away from specialty pharmaceuticals or provide a witness pursuant to Court of Chancery Rule 30(b)(6) on the topic, claiming that the subject was not relevant. BTG also objected to Makin being identified as a custodian for documents, claiming that she did not possess relevant information. These positions could not have been asserted in good faith, yet BTG forced Wellstat to prevail on a motion to compel before BTG complied with its discovery obligations.

Equally concerning, at trial BTG presented a misleading demonstrative regarding the calculation of Wellstat’s damages.

[bargainbob] 10/7/2018 18:19

I saw someone bought yesterday .

[spyder] 10/7/2018 17:56

A quote from Andy Burrows in response to another shareholder back in early June -
"I expect there to be support for the shares, but in these markets investors tend to wait to see how low they can buy for …"
Clearly the investors are still waiting and the shares keep going lower …
How prescient of Mr Burrows.

[bargainbob] 10/7/2018 17:31

No wonder management sucking as much out as possible , before it goes pop.